IDO1 and graft versus host disease: recently demonstrated that compared to naïve MSCs, human MSCs primed with IFN-γ significantly upregulated IDO expression, increased immunosuppressive activity in vitro, and reduced GVHD symptoms and mortality a NOD-SCID PBMC-transplanted mouse model (55).